172 related articles for article (PubMed ID: 17716712)
1. CA-125 level preoperative assessment in early and advanced ovarian carcinoma.
Raspollini MR
Gynecol Oncol; 2007 Nov; 107(2):356-7; author reply 357-8. PubMed ID: 17716712
[No Abstract] [Full Text] [Related]
2. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
3. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
[TBL] [Abstract][Full Text] [Related]
4. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
5. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
6. [Application of multi-tumor markers in ovarian carcinoma].
Feng J; Qian H; Tian Y
Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
[TBL] [Abstract][Full Text] [Related]
7. [Ovarian neoplasms and tumor markers].
Zarcone R; Candido R; Cardone G; De Luca P; Voto RI; Bellini P
Minerva Ginecol; 1994 Oct; 46(10):531-3. PubMed ID: 7838408
[TBL] [Abstract][Full Text] [Related]
8. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
9. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund B
Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
[No Abstract] [Full Text] [Related]
10. [Expression of CA-125 in ovarian cancer].
Mircea R; Frîncu DL; Dumitrache F
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
[TBL] [Abstract][Full Text] [Related]
11. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
Prat A; Parera M; Del Campo JM
J Clin Oncol; 2008 Apr; 26(10):1771-2; author reply 1772. PubMed ID: 18375912
[No Abstract] [Full Text] [Related]
13. StatBite: Ovarian cancer: risk of recurrence by stage of diagnosis.
J Natl Cancer Inst; 2009 Sep; 101(18):1234. PubMed ID: 19738164
[No Abstract] [Full Text] [Related]
14. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
[TBL] [Abstract][Full Text] [Related]
15. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
16. [Preoperative diagnosis of malignancy of ovarian space-occupying lesions with special reference to new, laparoscopic surgical techniques].
Roch G
Wien Klin Wochenschr; 1995; 107(17):529-31. PubMed ID: 7483637
[No Abstract] [Full Text] [Related]
17. A step forward for two-step screening for ovarian cancer.
Hensley ML
J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
[No Abstract] [Full Text] [Related]
18. Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125.
Berek JS
Gynecol Oncol; 2000 May; 77(2):225-6. PubMed ID: 10785468
[No Abstract] [Full Text] [Related]
19. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
20. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis.
Chopra V; Dinh TV; Hannigan EV
Cancer J Sci Am; 1996; 2(5):279-85. PubMed ID: 9166545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
